With the success of mRNA-based Covid vaccines, there is now great momentum to develop mRNA-based therapeutics to cure previously incurable diseases. One major hurdle in successfully deploying mRNA therapy is the difficulty in obtaining mRNA without product-related impurities - double stranded RNA (dsRNA), long RNA impurities (LRNA) and short truncated RNA (stRNA). Current production methods, without additional purification steps to remove these impurities, can potentially result in mRNA with increased immunogenicity and compromised efficacy in applications such as CRISPR gene editing, protein replacement therapies, and other advanced biotechnological solutions employing mRNA.